SUBSCRIBE
SUBSCRIBE

Brandon May

CVnCoV helping the COVID-19 patients.
Drug Development
Study: CureVac’s COVID-19 Vaccine CVnCoV Produces Immune Responses in Healthy Volunteers
Newly announced results of a Phase I dose-escalation study show CureVac’s COVID-19 vaccine candidate, CVnCoV, generates noticeable immune responses in healthy volunteers.
November 2, 2020
 · 
3 min read
 · 
Brandon May
Drug Development
Regeneron Halts Enrollment of Critically Ill Patients in COVID-19 Antibody Trial
The decision to halt critically ill patients was made in response to Regeneron’s independent safety board finding a potential safety signal and an unfavorable risk-benefit profile of the monoclonal antibody therapy in a subgroup of patients requiring high-flow oxygen or mechanical ventilation.
October 30, 2020
 · 
3 min read
 · 
Brandon May
Pictured: Regeneron logo on a light brown building
Drug Development
Regeneron’s REGN-COV2 Cocktail Meets Clinical Endpoints in Phase II/III Trial
The positive findings were shared as part of the company’s Emergency Use Authorization submission for its investigational COVID-19 therapy.
October 30, 2020
 · 
3 min read
 · 
Brandon May
BioCapital
Pharma Companies Strike Deals to Deliver Millions of COVID-19 Vaccines by 2021
BioSpace provides an up-to-date overview of these deals and the projected COVID-19 vaccine doses each company plans to have within the next couple of years.
October 29, 2020
 · 
4 min read
 · 
Brandon May
CStone’s chairman and chief executive officer, Fra
Business
CStone Enters $1 Billion Deal with EQRx to Advance Immunotherapy Agents
The agreement provides exclusive rights to EQRx for CStone’s late-stage immuno-oncology anti-PD-L1 monoclonal antibody sugemalimab and anti-PD-1 CS1003.
October 27, 2020
 · 
3 min read
 · 
Brandon May
Drug Development
FORMA Therapeutics’ Olutasidenib Shows Promising Activity Against IDH1-Mutated AML
Treatment with FORMA Therapeutics’ investigational agent olutasidenib has shown promising efficacy and safety in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and mutations in isocitrate dehydrogenase 1 (IDH1m).
October 26, 2020
 · 
4 min read
 · 
Brandon May
Finerenone is showing hopeful results.
Drug Development
Study Suggests Bayer’s Finerenone Slows CKD Progression in Patients With Kidney Disease and T2D
The findings from Finerenone’s study were presented at the virtual American Society of Nephrology’s (ASN) Kidney Week 2020 on October 23, and the full study was published in a recent online edition of the New England Journal of Medicine.
October 23, 2020
 · 
3 min read
 · 
Brandon May
Drug Development
Moderna Fully Enrolls 30,000-Person COVID-19 Vaccine Trial, Boosts Minority Participation
Moderna has fully enrolled its late-stage coronavirus disease 2019 (COVID-19) vaccine trial by hitting its target of 30,000 participants. More than one-third of this cohort includes minority participants.
October 22, 2020
 · 
3 min read
 · 
Brandon May
Policy
Purdue Pharma Agrees to $8 Billion DOJ Settlement Over Opioid Marketing Practices
The settlement stems from multi-year criminal and civil investigations into Purdue’s marketing practices related to its powerful prescription painkiller, OxyContin, which critics have argued facilitated the opioid epidemic.
October 21, 2020
 · 
3 min read
 · 
Brandon May
Job Trends
Roche Canada Puts Five-Year Plan into Motion to Create 500 New Jobs in Ontario
Roche Canada is making a $500 million investment to expand its Canadian pharmaceutical headquarters in Ontario, which the company said will bring up to 500 new full-time jobs to the region over the next five years.
October 21, 2020
 · 
2 min read
 · 
Brandon May
Business
Genesis Therapeutics and Genentech Enter AI-Driven Drug Discovery Collaboration
In this multi-target partnership, Genentech will leverage Genesis’ Dynamic PotentialNet AI platform and other novel neural network algorithms.
October 19, 2020
 · 
3 min read
 · 
Brandon May
Business
UCB Snags Eli Lilly U.K. Research Site, Plans to Invest £1 Billion Over Five Years for R&D
UCB is investing more than £1 billion over five years to expand its research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.
October 16, 2020
 · 
2 min read
 · 
Brandon May
Genetown
Moderna Works With International Regulators to Speed Up COVID-19 Vaccine Review Process
Moderna is working with international regulators to accelerate approval of the company’s COVID-19 vaccine candidate, mRNA-1273.
October 15, 2020
 · 
3 min read
 · 
Brandon May
Drug Development
Pros and Cons of the Common Types of COVID-19 Tests
While COVID-19 tests have been crucial in identifying and tracking cases of infection and disease-related morbidity and mortality, they aren’t without their potential drawbacks.
October 14, 2020
 · 
5 min read
 · 
Brandon May
Business
Takeda Joins Forces with Accenture, AWS to Transform to Cloud-Based Company
Takeda has entered into a five-year agreement with Accenture and Amazon Web Services (AWS) to support the Tokyo-based pharmaceutical company in moving 80% of its applications to the “cloud” and modernizing the company’s research tools.
October 14, 2020
 · 
3 min read
 · 
Brandon May
Load More